These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21362515)

  • 1. Molecular magnetic resonance contrast agents for the detection of cancer: past and present.
    Bogdanov A; Mazzanti ML
    Semin Oncol; 2011 Feb; 38(1):42-54. PubMed ID: 21362515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance in the era of molecular imaging of cancer.
    Gore JC; Manning HC; Quarles CC; Waddell KW; Yankeelov TE
    Magn Reson Imaging; 2011 Jun; 29(5):587-600. PubMed ID: 21524870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe.
    Misri R; Meier D; Yung AC; Kozlowski P; Häfeli UO
    Nanomedicine; 2012 Aug; 8(6):1007-16. PubMed ID: 22100757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heading toward Macromolecular and Nanosized Bioresponsive MRI Probes for Successful Functional Imaging.
    Angelovski G
    Acc Chem Res; 2017 Sep; 50(9):2215-2224. PubMed ID: 28841293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles.
    Dassler K; Roohi F; Lohrke J; Ide A; Remmele S; Hütter J; Pietsch H; Pison U; Schütz G
    Invest Radiol; 2012 Jul; 47(7):383-91. PubMed ID: 22659596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing MR probes for molecular imaging.
    McMahon MT; Chan KW
    Adv Cancer Res; 2014; 124():297-327. PubMed ID: 25287693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular imaging in cardiovascular diseases.
    Botnar RM; Ebersberger H; Noerenberg D; Jansen CH; Wiethoff AJ; Schuster A; Kasner M; Walter TC; Knobloch G; Hoppe P; Diederichs G; Hamm B; Makowski MR
    Rofo; 2015 Feb; 187(2):92-101. PubMed ID: 25585260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The medicinal chemistry of targeted tumor imaging (II).
    Chen XS
    Curr Top Med Chem; 2010; 10(12):1145-6. PubMed ID: 20681946
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoconjugate probes and targets for molecular imaging using magnetic resonance.
    Geraldes CF; Djanashvili K; Peters JA
    Future Med Chem; 2010 Mar; 2(3):409-25. PubMed ID: 21426175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast (T1/T2) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis.
    Xue S; Zhang C; Yang Y; Zhang L; Cheng D; Zhang J; Shi H; Zhang Y
    J Biomed Nanotechnol; 2015 Jun; 11(6):1027-37. PubMed ID: 26353592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mono-dispersed high magnetic resonance sensitive magnetite nanocluster probe for detection of nascent tumors by magnetic resonance molecular imaging.
    Zhang C; Xie X; Liang S; Li M; Liu Y; Gu H
    Nanomedicine; 2012 Aug; 8(6):996-1006. PubMed ID: 22197723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular imaging with targeted contrast agents.
    Makowski MR; Wiethoff AJ; Jansen CH; Botnar RM
    Top Magn Reson Imaging; 2009 Aug; 20(4):247-59. PubMed ID: 20805735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging of extracellular matrix proteins with targeted probes using magnetic resonance imaging.
    Salarian M; Ibhagui OY; Yang JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1622. PubMed ID: 32126587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of nanoparticle based contrast agents in MRI: a molecular imaging perspective.
    Oghabian MA; Farahbakhsh NM
    J Biomed Nanotechnol; 2010 Jun; 6(3):203-13. PubMed ID: 21179937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polypeptide-Based, Membrane-Penetrating, Target-Specific Contrast Agent for Magnetic Resonance Molecular Imaging.
    Yu K; Yu Y; Yao Y; Wu Z; Fu S; Cheng RH; Chen YW; Chen HY; Zhou J; Hwang DW; Ding S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1597-1604. PubMed ID: 35014508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
    Johansen ML; Gao Y; Hutnick MA; Craig SEL; Pokorski JK; Flask CA; Brady-Kalnay SM
    Anal Chem; 2017 Jun; 89(11):5932-5939. PubMed ID: 28481080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An introduction to functional and molecular imaging with MRI.
    Gallagher FA
    Clin Radiol; 2010 Jul; 65(7):557-66. PubMed ID: 20541655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of contrast agents targeted to the tumor vasculature in molecular magnetic resonance imaging.
    Oostendorp M; Douma K; Hackeng TM; van Zandvoort MA; Post MJ; Backes WH
    Contrast Media Mol Imaging; 2010; 5(1):9-17. PubMed ID: 20101742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemistry of tumour targeted T1 based MRI contrast agents.
    Kamaly N; Miller AD; Bell JD
    Curr Top Med Chem; 2010; 10(12):1158-83. PubMed ID: 20388110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents.
    Pu F; Xue S; Qiao J; Patel A; Yang JJ
    Curr Protein Pept Sci; 2016; 17(6):519-33. PubMed ID: 26721404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.